Candel Therapeutics (CADL) Accounts Payables (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Accounts Payables data on file, last reported at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 376.37% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (up 376.37% YoY), and the FY2025 full-year result was $1.1 million, up 376.37% from the prior year.
• Accounts Payables improved to $1.1 million in Q4 2025, from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.0 million in Q2 2025 to a low of $237000.0 in Q4 2024.
• A 5-year average of $828210.5 and a median of $759000.0 in 2021 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 76.1% in 2022 and soared 376.37% in 2025, its largest moves.
• Tracing CADL's Accounts Payables over 5 years: stood at $1.6 million in 2021, then slumped by 76.1% to $380000.0 in 2022, then grew by 11.05% to $422000.0 in 2023, then plunged by 43.84% to $237000.0 in 2024, then soared by 376.37% to $1.1 million in 2025.
• Business Quant data shows CADL's Accounts Payables at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $2.0 million in Q2 2025.